Estrogen Regulation of Mitochondrial Bioenergetics. Implications for Prevention of Alzheimer's Disease

Advances in Pharmacology

Volumn 64, Issue , 2012, Pages 327-371

  Yao, Jia ^a   Brinton, Roberta Diaz ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Bioenergetics; Estrogen; Healthy cell bias; Mitochondria; White matter degeneration

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FLORBETAPIR F 18; FLUORODEOXYGLUCOSE F 18; FREE RADICAL; GAMMA SECRETASE; HYDROGEN PEROXIDE; PHOSPHOLIPASE A2; PITTSBURGH COMPOUND B; SOMATOMEDIN C; SUPEROXIDE; TAU PROTEIN;

ALZHEIMER DISEASE; AMNESIA; ANAEROBIC GLYCOLYSIS; ARTICLE; BRAIN ATROPHY; BRAIN BLOOD FLOW; BRAIN METABOLISM; CALCIUM HOMEOSTASIS; CELL ENERGY; CELL SURVIVAL; CELL VIABILITY; CITRIC ACID CYCLE; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL (TOPIC); DEMENTIA; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFECT; DRUG MECHANISM; ENERGY YIELD; FATTY ACID OXIDATION; GLUCOSE METABOLISM; GLYCOLYSIS; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; IN VIVO STUDY; KETOGENESIS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MENOPAUSE; NERVE CELL; NERVE CELL DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PATHOGENESIS; PERSONALITY DISORDER; PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY CHAIN; SENILE PLAQUE; SIGNAL TRANSDUCTION; TWO DIMENSIONAL GEL ELECTROPHORESIS; WHITE MATTER;

EID: 84864311250     PISSN: 10543589     EISSN: 15578925     Source Type: Book Series    
DOI: 10.1016/B978-0-12-394816-8.00010-6     Document Type: Chapter

References (239)

1. Alzheimer's Association. (2011). Alzheimer's Disease Facts and Figures, 12-13.
2. Arevalo M.A., Ruiz-Palmero I., Scerbo M.J., Acaz-Fonseca E., Cambiasso M.J., Garcia-Segura L.M. Molecular mechanisms involved in the regulation of neuritogenesis by estradiol: Recent advances. The Journal of Steroid Biochemistry and Molecular Biology 2012, 131(1-2):52-56.
3. Armstrong R.A. The pathogenesis of Alzheimer's disease: A reevaluation of the "amyloid cascade hypothesis." International Journal of Alzheimer's Disease 2011, 2011:630865.
4. Asthana S., Brinton R.D., Henderson V.W., McEwen B.S., Morrison J.H., Schmidt P.J. Frontiers proposal. National Institute on Aging "bench to bedside: estrogen as a case study" AGE 2009, 31(3):199-210.
5. Atamna H., Frey W.H. Mechanisms of mitochondrial dysfunction and energy deficiency in Alzheimer's disease. Mitochondrion 2007, 7(5):297-310.
6. Auestad N., Korsak R.A., Morrow J.W., Edmond J. Fatty acid oxidation and ketogenesis by astrocytes in primary culture. Journal of Neurochemistry 1991, 56(4):1376-1386.
7. Bartzokis G., Sultzer D., Lu P.H., Nuechterlein K.H., Mintz J., Cummings J.L. Heterogeneous age-related breakdown of white matter structural integrity: implications for cortical "disconnection" in aging and Alzheimer's disease. Neurobiology of Aging 2004, 25(7):843-851.
8. Beal M.F. Mitochondria take center stage in aging and neurodegeneration. Annals of Neurology 2005, 58(4):495-505.
9. Berent-Spillson A., Persad C.C., Love T., Tkaczyk A., Wang H., Reame N.K., et al. Early menopausal hormone use influences brain regions used for visual working memory. [Comparative Study Research Support, N.I.H., Extramural]. Menopause 2010, 17(4):692-699.
10. Bero A.W., Yan P., Roh J.H., Cirrito J.R., Stewart F.R., Raichle M.E., et al. Neuronal activity regulates the regional vulnerability to amyloid-beta deposition. Nature Neuroscience 2011, 14(6):750-756.
11. Bettini E., Maggi A. Estrogen induction of cytochrome c oxidase subunit III in rat hippocampus. Journal of Neurochemistry 1992, 58(5):1923-1929.
12. Bishop J., Simpkins J.W. Estradiol enhances brain glucose uptake in ovariectomized rats. Brain Research Bulletin 1995, 36(3):315-320.
13. Blalock E.M., Chen K.C., Sharrow K., Herman J.P., Porter N.M., Foster T.C., et al. Gene microarrays in hippocampal aging: Statistical profiling identifies novel processes correlated with cognitive impairment. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2003, 23(9):3807-3819.
14. Blalock E.M., Geddes J.W., Chen K.C., Porter N.M., Markesbery W.R., Landfield P.W. Incipient Alzheimer's disease: Microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proceedings of the National Academy of Sciences of the United States of America 2004, 101(7):2173-2178.
15. Blass J., Sheu R., Gibson G. Inherent abnormalities in energy metabolism in Alzheimer disease. Interaction with cerebrovascular compromise. Annals of the New York Academy of Sciences 2000, 903:204-221.
16. Blennow K., Vanmechelen E., Hampel H. CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. [Research Support, Non-U.S. Gov't Review]. Molecular Neurobiology 2001, 24(1-3):87-97.
17. Borras C., Gambini J., Vina J. Mitochondrial oxidant generation is involved in determining why females live longer than males. Frontiers in Bioscience 2007, 12:1008-1013.
18. Bosetti F., Brizzi F., Barogi S., Mancuso M., Siciliano G., Tendi E.A., et al. Cytochrome c oxidase and mitochondrial F1F0-ATPase (ATP synthase) activities in platelets and brain from patients with Alzheimer's disease. [Comparative Study Research Support, Non-U.S. Gov't]. Neurobiology of Aging 2002, 23(3):371-376.
19. Brewer G.J., Reichensperger J.D., Brinton R.D. Prevention of age-related dysregulation of calcium dynamics by estrogen in neurons. Neurobiology of Aging 2006, 27(2):306-317.
20. Brinton R.D. Cellular and molecular mechanisms of estrogen regulation of memory function and neuroprotection against Alzheimer's disease: Recent insights and remaining challenges. Learning & Memory 2001, 8(3):121-133.
21. Brinton R.D. Investigative models for determining hormone therapy-induced outcomes in brain: Evidence in support of a healthy cell bias of estrogen action. Annals of the New York Academy of Sciences 2005, 1052:57-74.
22. Brinton R.D. Estrogen regulation of glucose metabolism and mitochondrial function: Therapeutic implications for prevention of Alzheimer's disease. Advanced Drug Delivery Reviews 2008, 60(13-14):1504-1511.
23. Brinton R.D. The healthy cell bias of estrogen action: Mitochondrial bioenergetics and neurological implications. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review]. Trends in Neurosciences 2008, 31(10):529-537.
24. Brinton R.D., Chen S., Montoya M., Hsieh D., Minaya J., Kim J., et al. The women's health initiative estrogen replacement therapy is neurotrophic and neuroprotective. Neurobiology of Aging 2000, 21(3):475-496.
25. Burns M., Gaynor K., Olm V., Mercken M., LaFrancois J., Wang L., et al. Presenilin redistribution associated with aberrant cholesterol transport enhances beta-amyloid production in vivo. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2003, 23(13):5645-5649.
26. Cadenas E. Mitochondrial free radical production and cell signaling. Molecular Aspects of Medicine 2004, 25(1-2):17-26.
27. Cardona-Gomez G.P., Mendez P., DonCarlos L.L., Azcoitia I., Garcia-Segura L.M. Interactions of estrogen and insulin-like growth factor-I in the brain: molecular mechanisms and functional implications. The Journal of Steroid Biochemistry and Molecular Biology 2002, 83(1-5):211-217.
28. Cardoso S.M., Proenca M.T., Santos S., Santana I., Oliveira C.R. Cytochrome c oxidase is decreased in Alzheimer's disease platelets. [Comparative Study]. Neurobiology of Aging 2004, 25(1):105-110.
29. Cardoso S.M., Santana I., Swerdlow R.H., Oliveira C.R. Mitochondria dysfunction of Alzheimer's disease cybrids enhances Abeta toxicity. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. Journal of Neurochemistry 2004, 89(6):1417-1426.
30. Cardoso S.M., Santos S., Swerdlow R.H., Oliveira C.R. Functional mitochondria are required for amyloid beta-mediated neurotoxicity. The FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology 2001, 15(8):1439-1441.
31. Carmichael O., Schwarz C., Drucker D., Fletcher E., Harvey D., Beckett L., et al. Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative. [Clinical Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. Archives of Neurology 2010, 67(11):1370-1378.
32. Carro E., Trejo J.L., Gomez-Isla T., LeRoith D., Torres-Aleman I. Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nature Medicine 2002, 8(12):1390-1397.
33. Chen K., Reiman E.M., Alexander G.E., Caselli R.J., Gerkin R., Bandy D., et al. Correlations between apolipoprotein E epsilon4 gene dose and whole brain atrophy rates. American Journal of Psychiatry 2007, 164(6):916-921.
34. Chen S., Nilsen J., Brinton R.D. Dose and temporal pattern of estrogen exposure determines neuroprotective outcome in hippocampal neurons: Therapeutic implications. Endocrinology 2006, 147(11):5303-5313.
35. Cheng C.M., Cohen M., Tseng V., Bondy C.A. Endogenous IGF1 enhances cell survival in the postnatal dentate gyrus. Journal of Neuroscience Research 2001, 64(4):341-347.
36. Cheng C.M., Cohen M., Wang J., Bondy C.A. Estrogen augments glucose transporter and IGF1 expression in primate cerebral cortex. The FASEB journal: Official Publication of the Federation of American Societies for Experimental Biology 2001, 15(6):907-915.
37. Cheskis B.J., Greger J., Cooch N., McNally C., McLarney S., Lam H.S., et al. MNAR plays an important role in ERa activation of Src/MAPK and PI3K/Akt signaling pathways. [Review]. Steroids 2008, 73(9-10):901-905.
38. Chetelat G., Desgranges B., de la Sayette V., Viader F., Eustache F., Baron J.C. Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease? [Research Support, Non-U.S. Gov't]. Neurology 2003, 60(8):1374-1377.
39. Choi S.R., Golding G., Zhuang Z., Zhang W., Lim N., Hefti F., et al. Preclinical properties of 18F-AV-45: A PET agent for Abeta plaques in the brain. [Research Support, N.I.H., Extramural]. Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine 2009, 50(11):1887-1894.
40. Chou J.L., Shenoy D.V., Thomas N., Choudhary P.K., Laferla F.M., Goodman S.R., et al. Early dysregulation of the mitochondrial proteome in a mouse model of Alzheimer's disease. [Research Support, Non-U.S. Gov't]. Journal of Proteomics 2011, 74(4):466-479.
41. Cordey M., Gundimeda U., Gopalakrishna R., Pike C.J. Estrogen activates protein kinase C in neurons: Role in neuroprotection. Journal of Neurochemistry 2003, 84(6):1340-1348.
42. de Leon M.J., Convit A., Wolf O.T., Tarshish C.Y., DeSanti S., Rusinek H., et al. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET). [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. Proceedings of the National Academy of Sciences of the United States of America 2001, 98(19):10966-10971.
43. De Meyer G., Shapiro F., Vanderstichele H., Vanmechelen E., Engelborghs S., De Deyn P.P., et al. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. [Research Support, Non-U.S. Gov't]. Archives of Neurology 2010, 67(8):949-956.
44. De Santi S., de Leon M.J., Rusinek H., Convit A., Tarshish C.Y., Roche A., et al. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiology of Aging 2001, 22(4):529-539.
45. Diana F.F., Silva Esteves A.R., Oliveira C.R., Cardoso S.M. The common upstream driver of Abeta and tau pathology in Alzheimer s disease. Current Alzheimer Research 2011, 8(5):563-572. Mitochondria.
46. Du H., Guo L., Yan S., Sosunov A.A., McKhann G.M., Yan S.S. Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. Proceedings of the National Academy of Sciences of the United States of America 2010, 107(43). 18675-18670.
47. Duckles S.P., Krause D.N., Stirone C., Procaccio V. Estrogen and mitochondria: A new paradigm for vascular protection?. Molecular Interventions 2006, 6(1):26-35.
48. Dumont M., Lin M.T., Beal M.F. Mitochondria and antioxidant targeted therapeutic strategies for Alzheimer's disease. [Research Support, N.I.H., Extramural Review]. Journal of Alzheimer's Disease: JAD 2010, 2(Suppl. 20):S633-S643.
49. Eberling J.L., Reed B.R., Coleman J.E., Jagust W.J. Effect of estrogen on cerebral glucose metabolism in postmenopausal women. [Research Support, U.S. Gov't, P.H.S.]. Neurology 2000, 55(6):875-877.
50. Eberling J.L., Wu C., Tong-Turnbeaugh R., Jagust W.J. Estrogen- and tamoxifen-associated effects on brain structure and function. [Comparative Study Research Support, Non-U.S. Gov't]. Neuroimage 2004, 21(1):364-371.
51. Fassbender K., Masters C., Beyreuther K. Alzheimer's disease: Molecular concepts and therapeutic targets. Naturwissenschaften 2001, 88(6):261-267.
52. Feldhaus P., Fraga D.B., Ghedim F.V., De Luca R.D., Bruna T.D., Heluany M., et al. Evaluation of respiratory chain activity in lymphocytes of patients with Alzheimer disease. Metabolic Brain Disease 2011, 26(3):229-236.
53. Fillit H., Weinreb H., Cholst I., Luine V., McEwen B., Amador R., et al. Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer's type. Psychoneuroendocrinology 1986, 11(3):337-345.
54. Garcia-Segura L.M., Arevalo M.A., Azcoitia I. Interactions of estradiol and insulin-like growth factor-I signalling in the nervous system: New advances. [Research Support, Non-U.S. Gov't Review]. Progress in Brain Research 2010, 181:251-272.
55. Garcia-Segura L.M., Cardona-Gomez G.P., Chowen J.A., Azcoitia I. Insulin-like growth factor-I receptors and estrogen receptors interact in the promotion of neuronal survival and neuroprotection. Journal of Neurocytology 2000, 29(5-6):425-437.
56. Gibson G.E., Sheu K.F., Blass J.P., Baker A., Carlson K.C., Harding B., et al. Reduced activities of thiamine-dependent enzymes in the brains and peripheral tissues of patients with Alzheimer's disease. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. Archives of Neurology 1988, 45(8):836-840.
57. Gibson G.E., Shi Q. A mitocentric view of Alzheimer's disease suggests multi-faceted treatments. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review]. Journal of Alzheimer's disease: JAD 2010, 2(Suppl. 20):S591-607.
58. Gleason C.E., Dowling N.M., Friedman E., Wharton W., Asthana S. Using predictors of hormone therapy use to model the healthy user bias: How does healthy user status influence cognitive effects of hormone therapy?. Menopause 2011, 19(5):524-533.
59. Golde T.E., Schneider L.S., Koo E.H. Anti-abeta therapeutics in Alzheimer's disease: The need for a paradigm shift. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. Neuron 2011, 69(2):203-213.
60. Gorenstein C., Renno J., Vieira Filho A.H., Gianfaldoni A., Goncalves M.A., Halbe H.W., et al. Estrogen replacement therapy and cognitive functions in healthy postmenopausal women: A randomized trial. [Randomized Controlled Trial Research Support, Non-U.S. Gov't]. Archives of Women's Mental Health 2011, 14(5):367-373.
61. Gottlob K., Majewski N., Kennedy S., Kandel E., Robey R.B., Hay N. Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes & Development 2001, 15(11):1406-1418.
62. Guzman M., Blazquez C. Ketone body synthesis in the brain: Possible neuroprotective effects. Prostaglandins, Leukotrienes, and Essential Fatty Acids 2004, 70(3):287-292.
63. Hansson O., Zetterberg H., Buchhave P., Londos E., Blennow K., Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: A follow-up study. Lancet Neurology 2006, 5(3):228-234.
64. Hardy J. Alzheimer's disease: The amyloid cascade hypothesis: An update and reappraisal. Journal of Alzheimer's Disease 2006, 9(Suppl. 3):151-153.
65. Hardy J.A., Higgins G.A. Alzheimer's disease: The amyloid cascade receive hypothesis. [Review]. Science 1992, 256(5054):184-185.
66. Hauptmann S., Scherping I., Drose S., Brandt U., Schulz K.L., Jendrach M., et al. Mitochondrial dysfunction: An early event in Alzheimer pathology accumulates with age in AD transgenic mice. [Research Support, Non-U.S. Gov't]. Neurobiology of Aging 2009, 30(10):1574-1586.
67. Henderson S.T. Ketone bodies as a therapeutic for Alzheimer's disease. [Review]. Neurotherapeutics: The Journal of the American Society for Experimental NeuroTherapeutics 2008, 5(3):470-480.
68. Henderson V.W., Brinton R.D. Menopause and mitochondria: Windows into estrogen effects on Alzheimer's disease risk and therapy. Progress in Brain Research 2010, 182:77-96.
69. Henderson V.W., Espeland M.A., Hogan P.E., Rapp S.R., Stefanick M.L., Wactawski-Wende J., Johnson K., et al. Prior use of hormone therapy and incident Alzheimer's disease in the Women's Health Initiative Memory Study. Neurology 2007, 68(Suppl. 1):A205.
70. Henderson V.W., Paganini-Hill A., Miller B.L., Elble R.J., Reyes P.F., Shoupe D., et al. Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial. Neurology 2000, 54(2):295-301.
71. Holmquist L., Stuchbury G., Berbaum K., Muscat S., Young S., Hager K., et al. Lipoic acid as a novel treatment for Alzheimer's disease and related dementias. Pharmacology & Therapeutics 2007, 113(1):154-164.
72. Hoyer S., Nitsch R., Oesterreich K. Predominant abnormality in cerebral glucose utilization in late-onset dementia of the Alzheimer type: A cross-sectional comparison against advanced late-onset and incipient early-onset cases. Journal of Neural Transmission. Parkinson's Disease and Dementia Section 1991, 3(1):1-14.
73. Huang Y.H., Zhang Q.H. Genistein reduced the neural apoptosis in the brain of ovariectomised rats by modulating mitochondrial oxidative stress. [Research Support, Non-U.S. Gov't]. The British Journal of Nutrition 2010, 104(9):1297-1303.
74. Ibanez V., Pietrini P., Alexander G.E., Furey M.L., Teichberg D., Rajapakse J.C., et al. Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease. Neurology 1998, 50(6):1585-1593.
75. Ikonomovic M.D., Klunk W.E., Abrahamson E.E., Mathis C.A., Price J.C., Tsopelas N.D., et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008, 131(Pt 6):1630-1645.
76. Imbimbo B.P., Giardina G.A. Gamma-secretase inhibitors and modulators for the treatment of Alzheimer's disease: Disappointments and Hopes. Current topics in Medicinal Chemistry 2011, 11(12):1555-1570.
77. Irwin R.W., Yao J., Hamilton R., Cadenas E., Brinton R.D., Nilsen J. Progesterone and estrogen regulate oxidative metabolism in brain mitochondria. Endocrinology 2008, 149(6):3167-3175.
78. Irwin R.W., Yao J., To J., Hamilton R.T., Cadenas E., Brinton R.D. Selective oestrogen receptor modulators differentially potentiate brain mitochondrial function. Journal of Neuroendocrinology 2012, 24(1):236-248.
79. Ishii K., Sasaki M., Kitagaki H., Yamaji S., Sakamoto S., Matsuda K., et al. Reduction of cerebellar glucose metabolism in advanced Alzheimer's disease. Journal of Nuclear Medicine 1997, 38(6):925-928.
80. Jack C.R., Knopman D.S., Jagust W.J., Shaw L.M., Aisen P.S., Weiner M.W., et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. [Research Support, N.I.H., Extramural]. Lancet Neurology 2010, 9(1):119-128.
81. Jack C.R., Lowe V.J., Senjem M.L., Weigand S.D., Kemp B.J., Shiung M.M., et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. [Comparative Study Evaluation Studies Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. Brain: A Journal of Neurology 2008, 131(Pt 3):665-680.
82. Jagust W., Gitcho A., Sun F., Kuczynski B., Mungas D., Haan M. Brain imaging evidence of preclinical Alzheimer's disease in normal aging. Annals of Neurology 2006, 59(4):673-681.
83. Jia Yao S.C., Mao Zisu, Cadenas Enrique, Brinton Roberta Diaz 2-Deoxy-D-Glucose Treatment Induces Ketogenesis, Sustains Mitochondrial Function, and Reduces Pathology in Female Mouse Model of Alzheimer's Disease. PLoS One 2011, 6(7). e21788.
84. Joffe H., Hall J.E., Gruber S., Sarmiento I.A., Cohen L.S., Yurgelun-Todd D., et al. Estrogen therapy selectively enhances prefrontal cognitive processes: A randomized, double-blind, placebo-controlled study with functional magnetic resonance imaging in perimenopausal and recently postmenopausal women. [Randomized Controlled Trial Research Support, Non-U.S. Gov't]. Menopause 2006, 13(3):411-422.
85. Karuppagounder S.S., Pinto J.T., Xu H., Chen H.L., Beal M.F., Gibson G.E. Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. Neurochemistry International 2009, 54(2):111-118.
86. Khan S.M., Cassarino D.S., Abramova N.N., Keeney P.M., Borland M.K., Trimmer P.A., et al. Alzheimer's disease cybrids replicate beta-amyloid abnormalities through cell death pathways. [Research Support, U.S. Gov't, P.H.S.]. Annals of Neurology 2000, 48(2):148-155.
87. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Annals of Neurology 2004, 55(3):306-319.
88. Knopman D.S., Parisi J.E., Salviati A., Floriach-Robert M., Boeve B.F., Ivnik R.J., et al. Neuropathology of cognitively normal elderly. [Comparative Study Research Support, U.S. Gov't, P.H.S.]. Journal of Neuropathology and Experimental Neurology 2003, 62(11):1087-1095.
89. Kostanyan A., Nazaryan K. Rat brain glycolysis regulation by estradiol-17 beta. Biochimica et Biophysica Acta 1992, 1133(3):301-306.
90. Kuczynski B., Targan E., Madison C., Weiner M., Zhang Y., Reed B., et al. White matter integrity and cortical metabolic associations in aging and dementia. Alzheimers & Dementia 2010, 6(1):54-62.
91. Levin E.R. Cell localization, physiology, and nongenomic actions of estrogen receptors. Journal of Applied Physiology 2001, 91(4):1860-1867.
92. Liang W.S., Reiman E.M., Valla J., Dunckley T., Beach T.G., Grover A., et al. Alzheimer's disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons. Proceedings of the National Academy of Sciences of the United States of America 2008, 105(11):4441-4446.
93. Lin M., Beal M. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006, 443(7113):787-795.
94. Lopez J.R., Lyckman A., Oddo S., Laferla F.M., Querfurth H.W., Shtifman A. Increased intraneuronal resting [Ca(2+)] in adult Alzheimer's disease mice. Journal of Neurochemistry 2007, 105(1):262-271.
95. Lopez-Grueso R., Borras C., Gambini J., Vina J. Aging and ovariectomy cause a decrease in brain glucose consumption in vivo in Wistar rats. [Research Support, Non-U.S. Gov't]. Revista Espanola de Geriatria y Gerontologia 2010, 45(3):136-140.
96. Lustbader J.W., Cirilli M., Lin C., Xu H.W., Takuma K., Wang N., et al. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science 2004, 304(5669):448-452.
97. Magistretti P.J. Neuron-glia metabolic coupling and plasticity. The Journal of Experimental Biology 2006, 209(Pt 12):2304-2311.
98. Maki P.M., Dennerstein L., Clark M., Guthrie J., LaMontagne P., Fornelli D., et al. Perimenopausal use of hormone therapy is associated with enhanced memory and hippocampal function later in life. [Comparative Study Randomized Controlled Trial Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't]. Brain Research 2011, 1379:232-243.
99. Maki P.M., Resnick S.M. Longitudinal effects of estrogen replacement therapy on PET cerebral blood flow and cognition. Neurobiology of Aging 2000, 21(2):373-383.
100. Manczak M., Anekonda T.S., Henson E., Park B.S., Quinn J., Reddy P.H. Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: Implications for free radical generation and oxidative damage in disease progression. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.]. Human Molecular Genetics 2006, 15(9):1437-1449.
101. Mannella P., Brinton R.D. Estrogen receptor protein interaction with phosphatidylinositol 3-kinase leads to activation of phosphorylated Akt and extracellular signal-regulated kinase 1/2 in the same population of cortical neurons: A unified mechanism of estrogen action. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2006, 26(37):9439-9447.
102. Marambaud P., Zhao H., Davies P. Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. [Comparative Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. The Journal of Biological Chemistry 2005, 280(45):37377-37382.
103. McEwen B., Akama K., Alves S., Brake W.G., Bulloch K., Lee S., et al. Tracking the estrogen receptor in neurons: Implications for estrogen-induced synapse formation. Proceedings of the National Academy of Sciences of the United States of America 2001, 98(13):7093-7100.
104. Mendez P., Azcoitia I., Garcia-Segura L.M. Estrogen receptor alpha forms estrogen-dependent multimolecular complexes with insulin-like growth factor receptor and phosphatidylinositol 3-kinase in the adult rat brain. Brain Research. Molecular Brain Research 2003, 112(1-2):170-176.
105. Mendez P., Garcia-Segura L.M. Phosphatidylinositol 3-kinase and glycogen synthase kinase 3 regulate estrogen receptor-mediated transcription in neuronal cells. Endocrinology 2006, 147(6):3027-3039.
106. Mendez P., Wandosell F., Garcia-Segura L.M. Cross-talk between estrogen receptors and insulin-like growth factor-I receptor in the brain: Cellular and molecular mechanisms. Frontiers in Neuroendocrinology 2006, 27(4):391-403.
107. Miller J.A., Oldham M.C., Geschwind D.H. A systems level analysis of transcriptional changes in Alzheimer's disease and normal aging. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2008, 28(6):1410-1420.
108. Milner T.A., Ayoola K., Drake C.T., Herrick S.P., Tabori N.E., McEwen B.S., et al. Ultrastructural localization of estrogen receptor beta immunoreactivity in the rat hippocampal formation. The Journal of Comparative Neurology 2005, 491(2):81-95.
109. Milner T.A., Lubbers L.S., Alves S.E., McEwen B.S. Nuclear and extranuclear estrogen binding sites in the rat forebrain and autonomic medullary areas. Endocrinology 2008, 149(7):3306-3312.
110. Milner T.A., McEwen B.S., Hayashi S., Li C.J., Reagan L.P., Alves S.E. Ultrastructural evidence that hippocampal alpha estrogen receptors are located at extranuclear sites. Journal of Comparative Neurology 2001, 429(3):355-371.
111. Mintun M.A., Larossa G.N., Sheline Y.I., Dence C.S., Lee S.Y., Mach R.H., et al. [11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. Neurology 2006, 67(3):446-452.
112. Miyamoto S., Murphy A.N., Brown J.H. Akt mediates mitochondrial protection in cardiomyocytes through phosphorylation of mitochondrial hexokinase-II. Cell Death and Differentiation 2008, 15(3):521-529.
113. Molina J.A., de Bustos F., Jimenez-Jimenez F.J., Benito-Leon J., Gasalla T., Orti-Pareja M., et al. Respiratory chain enzyme activities in isolated mitochondria of lymphocytes from patients with Alzheimer's disease. [Clinical Trial Controlled Clinical Trial Research Support, Non-U.S. Gov't]. Neurology 1997, 48(3):636-638.
114. Moor A.N., Gottipati S., Mallet R.T., Sun J., Giblin F.J., Roque R., et al. A putative mitochondrial mechanism for antioxidative cytoprotection by 17beta-estradiol. [Research Support, U.S. Gov't, P.H.S.]. Experimental Eye Research 2004, 78(5):933-944.
115. Moreira P.I., Cardoso S.M., Santos M.S., Oliveira C.R. The key role of mitochondria in Alzheimer's disease. [Review]. Journal of Alzheimer's Disease: JAD 2006, 9(2):101-110.
116. Moreira P.I., Santos M.S., Seica R., Oliveira C.R. Brain mitochondrial dysfunction as a link between Alzheimer's disease and diabetes. Journal of the Neurological Sciences 2007, 257(1-2):206-214.
117. Moreira P.I., Zhu X., Wang X., Lee H.G., Nunomura A., Petersen R.B., et al. Mitochondria: A therapeutic target in neurodegeneration. Biochimica et Biophysica Acta 2010, 1802(1):212-220.
118. Morris A.A. Cerebral ketone body metabolism. [Review]. Journal of Inherited Metabolic Disease 2005, 28(2):109-121.
119. Morrison J.H., Brinton R.D., Schmidt P.J., Gore A.C. Estrogen, menopause, and the aging brain: How basic neuroscience can inform hormone therapy in women. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2006, 26(41):10332-10348.
120. Mosconi L., de Leon M., Murray J., E L., Lu J., Javier E., et al. Reduced mitochondria cytochrome oxidase activity in adult children of mothers with Alzheimer's disease. Journal of Alzheimer's Disease: JAD 2011, 27(3):483-490.
121. Mosconi L., De Santi S., Li J., Tsui W.H., Li Y., Boppana M., et al. Hippocampal hypometabolism predicts cognitive decline from normal aging. [Research Support, N.I.H., Extramural]. Neurobiology of Aging 2008, 29(5):676-692.
122. Mosconi L., McHugh P.F. FDG-and amyloid-PET in Alzheimer's disease: Is the whole greater than the sum of the parts?. The Quarterly Journal of Nuclear Medicine and Molecular Imaging: Official Publication of the Italian Association of Nuclear Medicine 2011, 55(3):250-264.
123. Mosconi L., Mistur R., Switalski R., Brys M., Glodzik L., Rich K., et al. Declining brain glucose metabolism in normal individuals with a maternal history of Alzheimer disease. Neurology 2009, 72(6):513-520.
124. Mosconi L., Mistur R., Switalski R., Tsui W.H., Glodzik L., Li Y., et al. FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. European Journal of Nuclear Medicine and Molecular Imaging 2009, 36(5):811-822.
125. Mulnard R.A., Cotman C.W., Kawas C., van Dyck C.H., Sano M., Doody R., et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: A randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA: The Journal of the American Medical Association 2000, 283(8):1007-1015.
126. Murphy A.N., Bredesen D.E., Cortopassi G., Wang E., Fiskum G. Bcl-2 potentiates the maximal calcium uptake capacity of neural cell mitochondria. Proceedings of the National Academy of Sciences of the United States of America 1996, 93(18):9893-9898.
127. Nicholson R.M., Kusne Y., Nowak L.A., LaFerla F.M., Reiman E.M., Valla J. Regional cerebral glucose uptake in the 3xTG model of Alzheimer's disease highlights common regional vulnerability across AD mouse models. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. Brain Research 2010, 1347:179-185.
128. Nilsen J., Brinton R.D. Impact of progestins on estradiol potentiation of the glutamate calcium response. Neuroreport 2002, 13(6):825-830.
129. Nilsen J., Brinton R.D. Mechanism of estrogen-mediated neuroprotection: Regulation of mitochondrial calcium and Bcl-2 expression. Proceedings of the National Academy of Sciences of the United States of America 2003, 100(5):2842-2847.
130. Nilsen J., Brinton R.D. Mitochondria as therapeutic targets of estrogen action in the central nervous system. Current Drug Targets. CNS and Neurological Disorders 2004, 3(4):297-313.
131. Nilsen J., Chen S., Brinton R.D. Dual action of estrogen on glutamate-induced calcium signaling: mechanisms requiring interaction between estrogen receptors and src/mitogen activated protein kinase pathway. Brain Research 2002, 930(1-2):216-234.
132. Nilsen J., Chen S., Irwin R.W., Iwamoto S., Brinton R.D. Estrogen protects neuronal cells from amyloid beta-induced apoptosis via regulation of mitochondrial proteins and function. BMC Neuroscience 2006, 7:74.
133. Nilsen J., Irwin R.W., Gallaher T.K., Brinton R.D. Estradiol in vivo regulation of brain mitochondrial proteome. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2007, 27(51):14069-14077.
134. Nunomura A., Chiba S., Lippa C.F., Cras P., Kalaria R.N., Takeda A., et al. Neuronal RNA oxidation is a prominent feature of familial Alzheimer's disease. [Comparative Study Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. Neurobiology of Disease 2004, 17(1):108-113.
135. Nunomura A., Hofer T., Moreira P.I., Castellani R.J., Smith M.A., Perry G. RNA oxidation in Alzheimer disease and related neurodegenerative disorders. [Review]. Acta Neuropathologica 2009, 118(1):151-166.
136. Nunomura A., Perry G., Aliev G., Hirai K., Takeda A., Balraj E.K., et al. Oxidative damage is the earliest event in Alzheimer disease. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. Journal of Neuropathology and Experimental Neurology 2001, 60(8):759-767.
137. O'Dwyer L., Lamberton F., Bokde A.L., Ewers M., Faluyi Y.O., Tanner C., et al. Multiple indices of diffusion identifies white matter damage in mild cognitive impairment and Alzheimer's disease. PLoS One 2011, 6(6). e21745.
138. Ottowitz W.E., Derro D., Dougherty D.D., Lindquist M.A., Fischman A.J., Hall J.E. FDG-PET analysis of amygdalar-cortical network covariance during pre-versus post-menopausal estrogen levels: potential relevance to resting state networks, mood, and cognition. [Research Support, N.I.H., Extramural]. Neuro Endocrinology Letters 2008, 29(4):467-474.
139. Ottowitz W.E., Siedlecki K.L., Lindquist M.A., Dougherty D.D., Fischman A.J., Hall J.E. Evaluation of prefrontal-hippocampal effective connectivity following 24 hours of estrogen infusion: An FDG-PET study. [Research Support, N.I.H., Extramural]. Psychoneuroendocrinology 2008, 33(10):1419-1425.
140. Packer L., Cadenas E. Lipoic acid: Energy metabolism and redox regulation of transcription and cell signaling. Journal of Clinical Biochemistry and Nutrition 2011, 48(1):26-32.
141. Park L.C., Zhang H., Sheu K.F., Calingasan N.Y., Kristal B.S., Lindsay J.G., et al. Metabolic impairment induces oxidative stress, compromises inflammatory responses, and inactivates a key mitochondrial enzyme in microglia. [Research Support, U.S. Gov't, P.H.S.]. Journal of Neurochemistry 1999, 72(5):1948-1958.
142. Parker W.D. Cytochrome oxidase deficiency in Alzheimer's disease. [Research Support, U.S. Gov't, P.H.S.]. Annals of the New York Academy of Sciences 1991, 640:59-64.
143. Perry E.K., Perry R.H., Tomlinson B.E., Blessed G., Gibson P.H. Coenzyme A-acetylating enzymes in Alzheimer's disease: Possible cholinergic 'compartment' of pyruvate dehydrogenase. Neuroscience Letters 1980, 18(1):105-110.
144. Petanceska S.S., DeRosa S., Olm V., Diaz N., Sharma A., Thomas-Bryant T., et al. Statin therapy for Alzheimer's disease: Will it work?. Journal of Molecular Neuroscience 2002, 19(1-2):155-161.
145. Pimplikar S.W. Reassessing the amyloid cascade hypothesis of Alzheimer's disease. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review]. The International Journal of Biochemistry & Cell Biology 2009, 41(6):1261-1268.
146. Pratico D., Uryu K., Leight S., Trojanoswki J.Q., Lee V.M. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2001, 21(12):4183-4187.
147. Price J.L., Morris J.C. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. [Research Support, U.S. Gov't, P.H.S.]. Annals of Neurology 1999, 45(3):358-368.
148. Prins N.D., Visser P.J., Scheltens P. Can novel therapeutics halt the amyloid cascade? [Editorial]. Alzheimer's Research & Therapy 2010, 2(2):5.
149. Rasgon N.L., Silverman D., Siddarth P., Miller K., Ercoli L.M., Elman S., et al. Estrogen use and brain metabolic change in postmenopausal women. Neurobiology of Aging 2005, 26(2):229-235.
150. Razmara A., Sunday L., Stirone C., Wang X., Krause D., Duckles S., et al. Mitochondrial effects of estrogen are mediated by ER{alpha} in brain endothelial cells. The Journal of Pharmacology and Experimental Therapeutics 2008, 325(3):782-790.
151. Readnower R.D., Sauerbeck A.D., Sullivan P.G. Mitochondria, amyloid beta, and Alzheimer's disease. International Journal of Alzheimer's Disease 2011, 2011:104545.
152. Reddy P.H. Mitochondrial oxidative damage in aging and Alzheimer's disease: Implications for mitochondrially targeted antioxidant therapeutics. Journal of Biomedicine & Biotechnology 2006, 2006(3):31372.
153. Reddy P.H., Beal M.F. Amyloid beta, mitochondrial dysfunction and synaptic damage: Implications for cognitive decline in aging and Alzheimer's disease. Trends in Molecular Medicine 2008, 14(2):45-53.
154. Reiman E.M., Chen K., Alexander G.E., Caselli R.J., Bandy D., Osborne D., et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. Proceedings of the National Academy of Sciences of the United States of America 2004, 101(1):284-289.
155. Resnick S.M., Henderson V.W. Hormone therapy and risk of Alzheimer disease: A critical time. JAMA: The Journal of the American Medical Association 2002, 288(17):2170-2172.
156. Resnick S.M., Maki P.M., Golski S., Kraut M.A., Zonderman A.B. Effects of estrogen replacement therapy on PET cerebral blood flow and neuropsychological performance. Hormones and Behavior 1998, 34(2):171-182.
157. Rhein V., Song X., Wiesner A., Ittner L.M., Baysang G., Meier F., et al. Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. [Research Support, Non-U.S. Gov't]. Proceedings of the National Academy of Sciences of the United States of America 2009, 106(47):20057-20062.
158. Risacher S.L., Saykin A.J., West J.D., Shen L., Firpi H.A., McDonald B.C. Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort. Current Alzheimer Research 2009, 6(4):347-361.
159. Rocca W.A., Bower J.H., Maraganore D.M., Ahlskog J.E., Grossardt B.R., de Andrade M., et al. Increased risk of parkinsonism in women who underwent oophorectomy before menopause. Neurology 2007, 70(3):200-209.
160. Rocca W.A., Grossardt B.R., Shuster L.T. Oophorectomy, menopause, estrogen, and cognitive aging: The timing hypothesis. [Research Support, N.I.H., Extramural Review]. Neuro-Degenerative Diseases 2010, 7(1-3):163-166.
161. Rosen R.F., Ciliax B.J., Wingo T.S., Gearing M., Dooyema J., Lah J.J., et al. Deficient high-affinity binding of Pittsburgh compound B in a case of Alzheimer's disease. Acta Neuropathologica 2010, 119(2):221-233.
162. Rosenbloom M.H., Alkalay A., Agarwal N., Baker S.L., O'Neil J.P., Janabi M., et al. Distinct clinical and metabolic deficits in PCA and AD are not related to amyloid distribution. Neurology 2011, 76(21):1789-1796.
163. Rowe W.B., Blalock E.M., Chen K.C., Kadish I., Wang D., Barrett J.E., et al. Hippocampal expression analyses reveal selective association of immediate-early, neuroenergetic, and myelinogenic pathways with cognitive impairment in aged rats. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience 2007, 27(12):3098-3110.
164. Schioth H.B., Craft S., Brooks S.J., Frey W.H., Benedict C. Brain insulin signaling and Alzheimer's disease: Current evidence and future directions. Molecular Neurobiology 2011, 2011.
165. Schneider L.S., Insel P.S., Weiner M.W. Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's disease neuroimaging initiative. [Clinical Trial Comparative Study Multicenter Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. Archives of Neurology 2011, 68(1):58-66.
166. Shaywitz S.E., Shaywitz B.A., Pugh K.R., Fulbright R.K., Skudlarski P., Mencl W.E., et al. Effect of estrogen on brain activation patterns in postmenopausal women during working memory tasks. [Clinical Trial Randomized Controlled Trial Research Support, U.S. Gov't, P.H.S.]. JAMA: The Journal of the American Medical Association 1999, 281(13):1197-1202.
167. Sherwin B.B. The critical period hypothesis: can it explain discrepancies in the oestrogen-cognition literature?. Journal of Neuroendocrinology 2007, 19(2):77-81.
168. Sherwin B.B. Estrogen therapy: is time of initiation critical for neuroprotection? [Research Support, Non-U.S. Gov't Review]. Nature Reviews. Endocrinology 2009, 5(11):620-627.
169. Sherwin B.B. Estrogen and cognitive functioning in women: Lessons we have learned. Behavioral Neuroscience 2011, 126(1):123-127.
170. Sherwin B.B., Henry J.F. Brain aging modulates the neuroprotective effects of estrogen on selective aspects of cognition in women: A critical review. Frontiers in Neuroendocrinology 2008, 29(1):88-113.
171. Sherwin B.B., McGill J. Oestrogen plus progestin doubles the risk of dementia in post-menopausal women. Evidence-Based Mental Health 2003, 6(4):111.
172. Shi J., Simpkins J.W. 17 beta-Estradiol modulation of glucose transporter 1 expression in blood-brain barrier. The American Journal of Physiology 1997, 272(6 Pt 1):E1016-1022.
173. Shumaker S.A., Legault C., Kuller L., Rapp S.R., Thal L., Lane D.S., et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA: The Journal of the American Medical Association 2004, 291(24):2947-2958.
174. Shumaker S.A., Legault C., Rapp S.R., Thal L., Wallace R.B., Ockene J.K., et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: A randomized controlled trial. JAMA: The Journal of the American Medical Association 2003, 289(20):2651-2662.
175. Silva D.F., Esteves A.R., Arduino D.M., Oliveira C.R., Cardoso S.M. Amyloid-beta-induced mitochondrial dysfunction impairs the autophagic lysosomal pathway in a tubulin dependent pathway. Journal of Alzheimer's Disease: JAD 2011, 26(3):565-581.
176. Simon A.M., Frechilla D., del Rio J. [Perspectives on the amyloid cascade hypothesis of Alzheimer's disease]. [Research Support, Non-U.S. Gov't Review]. Revista de Neurologia 2010, 50(11):667-675.
177. Simoncini T., Hafezi-Moghadam A., Brazil D.P., Ley K., Chin W.W., Liao J.K. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 2000, 407(6803):538-541.
178. Simpkins J.W., Dykens J.A. Mitochondrial mechanisms of estrogen neuroprotection. Brain Research Reviews 2008, 57(2):421-430.
179. Simpkins J.W., Wang J., Wang X., Perez E., Prokai L., Dykens J.A. Mitochondria play a central role in estrogen-induced neuroprotection. Current Drug Targets. CNS and Neurological Disorders 2005, 4(1):69-83.
180. Singh M. Ovarian hormones elicit phosphorylation of Akt and extracellular-signal regulated kinase in explants of the cerebral cortex. Endocrine Journal-Uk 2001, 14(3):407-415.
181. Singh M., Setalo G., Guan X., Frail D.E., Toran-Allerand C.D. Estrogen-induced activation of the mitogen-activated protein kinase cascade in the cerebral cortex of estrogen receptor-alpha knock-out mice. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2000, 20(5):1694-1700.
182. Singh M., Sumien N., Kyser C., Simpkins J.W. Estrogens and progesterone as neuroprotectants: What animal models teach us. Frontiers in Bioscience 2008, 13:1083-1089.
183. Smith Y.R., Bowen L., Love T.M., Berent-Spillson A., Frey K.A., Persad C.C., et al. Early initiation of hormone therapy in menopausal women is associated with increased hippocampal and posterior cingulate cholinergic activity. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. The Journal of Clinical Endocrinology and Metabolism 2011, 96(11):E1761-1770.
184. Sohrabji F. Estrogen: A neuroprotective or proinflammatory hormone? Emerging evidence from reproductive aging models. Annals of the New York Academy of Sciences 2005, 1052:75-90.
185. Sommer B. Alzheimer's disease and the amyloid cascade hypothesis: Ten years on. [Review]. Current Opinion in Pharmacology 2002, 2(1):87-92.
186. Sorbi S., Bird E.D., Blass J.P. Decreased pyruvate dehydrogenase complex activity in Huntington and Alzheimer brain. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. Annals of Neurology 1983, 13(1):72-78.
187. Spencer-Segal J.L., Tsuda M.C., Mattei L., Waters E.M., Romeo R.D., Milner T.A., et al. Estradiol acts via estrogen receptors alpha and beta on pathways important for synaptic plasticity in the mouse hippocampal formation. Neuroscience 2011, 202:131-146.
188. Sperling R.A., Aisen P.S., Beckett L.A., Bennett D.A., Craft S., Fagan A.M., et al. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. [Research Support, Non-U.S. Gov't]. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 2011, 7(3):280-292.
189. Spulber G., Niskanen E., Macdonald S., Smilovici O., Chen K., Reiman E.M., et al. Whole brain atrophy rate predicts progression from MCI to Alzheimer's disease. Neurobiology of Aging 2008, 31(9):1601-1605.
190. Starkov A.A., Fiskum G., Chinopoulos C., Lorenzo B.J., Browne S.E., Patel M.S., et al. Mitochondrial alpha-ketoglutarate dehydrogenase complex generates reactive oxygen species. [Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.]. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2004, 24(36):7779-7788.
191. Stirone C., Boroujerdi A., Duckles S.P., Krause D.N. Estrogen receptor activation of phosphoinositide-3 kinase, akt, and nitric oxide signaling in cerebral blood vessels: rapid and long-term effects. Molecular Pharmacology 2005, 67(1):105-113.
192. Stirone C., Duckles S.P., Krause D.N., Procaccio V. Estrogen increases mitochondrial efficiency and reduces oxidative stress in cerebral blood vessels. Molecular Pharmacology 2005, 68(4):959-965.
193. Swerdlow R.H. Mitochondria in cybrids containing mtDNA from persons with mitochondriopathies. [Research Support, N.I.H., Extramural Review]. Journal of Neuroscience Research 2007, 85(15):3416-3428.
194. Swerdlow R.H., Burns J.M., Khan S.M. The Alzheimer's disease mitochondrial cascade hypothesis. [Research Support, N.I.H., Extramural Review]. Journal of Alzheimer's disease: JAD 2010, 2(Suppl. 20):S265-S279.
195. Swerdlow R.H., Khan S.M. The Alzheimer's disease mitochondrial cascade hypothesis: an update. Experimental Neurology 2009, 218(2):308-315.
196. Takuma K., Yao J., Huang J., Xu H., Chen X., Luddy J., et al. ABAD enhances Abeta-induced cell stress via mitochondrial dysfunction. The FASEB journal: Official Publication of the Federation of American Societies for Experimental Biology 2005, 19(6):597-598.
197. Tang M., Subbiah M.T. Estrogens protect against hydrogen peroxide and arachidonic acid induced DNA damage. [Research Support, U.S. Gov't, P.H.S.]. Biochimica et Biophysica Acta 1996, 1299(2):155-159.
198. Toescu E.C., Verkhratsky A., Landfield P.W. Ca2+ regulation and gene expression in normal brain aging. Trends in Neurosciences 2004, 27(10):614-620.
199. Trojanowski J.Q., Vandeerstichele H., Korecka M., Clark C.M., Aisen P.S., Petersen R.C., et al. Update on the biomarker core of the Alzheimer's disease neuroimaging initiative subjects. Alzheimers & Dementia 2010, 6(3):230-238.
200. Trushina E., McMurray C.T. Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases. Neuroscience 2007, 145(4):1233-1248.
201. Vaishnavi S.N., Vlassenko A.G., Rundle M.M., Snyder A.Z., Mintun M.A., Raichle M.E. Regional aerobic glycolysis in the human brain. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. Proceedings of the National Academy of Sciences of the United States of America 2010, 107(41):17757-17762.
202. Valla J., Schneider L., Niedzielko T., Coon K.D., Caselli R., Sabbagh M.N., et al. Impaired platelet mitochondrial activity in Alzheimer's disease and mild cognitive impairment. Mitochondrion 2006, 6(6):323-330.
203. Vetrivel K.S., Thinakaran G. Membrane rafts in Alzheimer's disease beta-amyloid production. Biochimica et Biophysica Acta 2010, 1801(8):860-867.
204. Villain N., Fouquet M., Baron J.C., Mezenge F., Landeau B., de La Sayette V., et al. Sequential relationships between grey matter and white matter atrophy and brain metabolic abnormalities in early Alzheimer's disease. Brain 2010, 133(11):3301-3314.
205. Vina J., Borras C., Gambini J., Sastre J., Pallardo F.V. Why females live longer than males: Control of longevity by sex hormones. Science of Aging Knowledge Environment 2005, 2005(23). pe17.
206. Vina J., Sastre J., Pallardo F.V., Gambini J., Borras C. Role of mitochondrial oxidative stress to explain the different longevity between genders: protective effect of estrogens. Free Radical Research 2006, 40(12):1359-1365.
207. Vingtdeux V., Dreses-Werringloer U., Zhao H., Davies P., Marambaud P. Therapeutic potential of resveratrol in Alzheimer's disease. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review]. BMC Neuroscience 2008, 2(Suppl. 9):S6.
208. Vlassenko A.G., Vaishnavi S.N., Couture L., Sacco D., Shannon B.J., Mach R.H., et al. Spatial correlation between brain aerobic glycolysis and amyloid-beta (Abeta) deposition. [Research Support, N.I.H., Extramural]. Proceedings of the National Academy of Sciences of the United States of America 2010, 107(41):17763-17767.
209. Wagner B.K., Kitami T., Gilbert T.J., Peck D., Ramanathan A., Schreiber S.L., et al. Large-scale chemical dissection of mitochondrial function. Nature Biotechnology 2008, 26(3):343-351.
210. Wallace D.C. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annual Review of Genetics 2005, 39:359-407.
211. Wang J., Xiong S., Xie C., Markesbery W.R., Lovell M.A. Increased oxidative damage in nuclear and mitochondrial DNA in Alzheimer's disease. Journal of Neurochemistry 2005, 93(4):953-962.
212. Whitmer R.A., Quesenberry C.P., Zhou J., Yaffe K. Timing of hormone therapy and dementia: The critical window theory revisited. [Comparative Study Research Support, N.I.H., Extramural]. Annals of Neurology 2011, 69(1):163-169.
213. Whitwell J.L., Przybelski S.A., Weigand S.D., Knopman D.S., Boeve B.F., Petersen R.C., et al. 3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease. Brain 2007, 130(Pt 7):1777-1786.
214. Williams R. Biomarkers: Warning signs. Nature 2011, 475(7355):S5-S7.
215. Wise P.M. Estrogen therapy: Does it help or hurt the adult and aging brain? Insights derived from animal models. Neuroscience 2006, 138(3):831-835.
216. Wollen K.A. Alzheimer's disease: The pros and cons of pharmaceutical, nutritional, botanical, and stimulatory therapies, with a discussion of treatment strategies from the perspective of patients and practitioners. [Review]. Alternative Nedicine Review: A Journal of Clinical Therapeutic 2010, 15(3):223-244.
217. Wong D.F., Rosenberg P.B., Zhou Y., Kumar A., Raymont V., Ravert H.T., et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). [Clinical Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine 2010, 51(6):913-920.
218. Woolley C.S. Acute effects of estrogen on neuronal physiology. Annual Review of Pharmacology and Toxicology 2007, 47:657-680.
219. Wu T.W., Brinton R.D. Estrogen membrane receptor imaging coupled with estradiol activation of intracellular calcium rise and ERK activation in single neurons 2004, Paper presented at the Society for Neuroscience Abstracts.
220. Wu T.W., Wang J.M., Chen S., Brinton R.D. 17Beta-estradiol induced Ca2+ influx via L-type calcium channels activates the Src/ERK/cyclic-AMP response element binding protein signal pathway and BCL-2 expression in rat hippocampal neurons: A potential initiation mechanism for estrogen-induced neuroprotection. Neuroscience 2005, 135(1):59-72.
221. Xing G., Dong M., Li X., Zou Y., Fan L., Wang X., et al. Neuroprotective effects of puerarin against beta-amyloid-induced neurotoxicity in PC12 cells via a PI3K-dependent signaling pathway. [Research Support, Non-U.S. Gov't]. Brain Research Bulletin 2011, 85(3-4):212-218.
222. Yaffe K. Hormone therapy and the brain: Deja vu all over again?. JAMA: the Journal of the American Medical Association 2003, 289(20):2717-2719.
223. Yaffe K., Sawaya G., Lieberburg I., Grady D. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA: the Journal of the American Medical Association 1998, 279(9):688-695.
224. Yager J.D., Chen J.Q. Mitochondrial estrogen receptors-new insights into specific functions. Trends in Endocrinology and Metabolism: TEM 2007, 18(3):89-91.
225. Yang S.H., Liu R., Perez E.J., Wen Y., Stevens S.M., Valencia T., et al. Mitochondrial localization of estrogen receptor beta. Proceedings of the National Academy of Sciences of the United States of America 2004, 101(12):4130-4135.
226. Yao J., Chen S., Cadenas E., Brinton R.D. Estrogen protection against mitochondrial toxin-induced cell death in hippocampal neurons: Antagonism by progesterone. [Comparative Study Research Support, N.I.H., Extramural Research Support, 1379, Non-U.S. Gov't]. Brain research 2011, 1379:2-10.
227. Yao J., Hamilton R.T., Cadenas E., Brinton R.D. Decline in mitochondrial bioenergetics and shift to ketogenic profile in brain during reproductive senescence. Biochimica et Biophysica Acta 2010, 1800(10):1121-1126.
228. Yao J., Irwin R., Chen S., Hamilton R., Cadenas E., Brinton R.D. Ovarian hormone loss induces bioenergetic deficits and mitochondrial beta-amyloid. Neurobiology of Aging 2011, 33:1507-1521.
229. Yao J., Irwin R.W., Zhao L., Nilsen J., Hamilton R.T., Brinton R.D. Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America 2009, 106(34):14670-14675.
230. Yao J., Petanceska S.S., Montine T.J., Holtzman D.M., Schmidt S.D., Parker C.A., et al. Aging, gender and APOE isotype modulate metabolism of Alzheimer's Abeta peptides and F-isoprostanes in the absence of detectable amyloid deposits. Journal of Neurochemistry 2004, 90(4):1011-1018.
231. Yao J., Rettberg J.R., Klosinski L.P., Cadenas E., Brinton R.D. Shift in brain metabolism in late onset Alzheimer's disease: Implications for biomarkers and therapeutic interventions. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. Molecular Aspects of Medicine 2011, 32(4-6):247-257.
232. Young K.J., Bennett J.P. The mitochondrial secret(ase) of Alzheimer's disease. [Research Support, N.I.H., Extramural Review]. Journal of Alzheimer's disease: JAD 2010, 2((Suppl. 20),):S381-400.
233. Zandi P.P., Carlson M.C., Plassman B.L., Welsh-Bohmer K.A., Mayer L.S., Steffens D.C., et al. Hormone replacement therapy and incidence of Alzheimer disease in older women: The Cache County Study. JAMA : the Journal of the American Medical Association 2002, 288(17):2123-2129.
234. Zhang Y., Schuff N., Jahng G.H., Bayne W., Mori S., Schad L., et al. Diffusion tensor imaging of cingulum fibers in mild cognitive impairment and Alzheimer disease. Neurology 2007, 68(1):13-19.
235. Zhao L., Brinton R.D. WHI and WHIMS follow-up and human studies of soy isoflavones on cognition. [Comparative Study Research Support, Non-U.S. Gov't Review]. Expert Review of Neurotherapeutics 2007, 7(11):1549-1564.
236. Zhao L., Mao Z., Brinton R.D. A select combination of clinically relevant phytoestrogens enhances estrogen receptor beta-binding selectivity and neuroprotective activities in vitro and in vivo. [Research Support, Non-U.S. Gov't]. Endocrinology 2009, 150(2):770-783.
237. Zhao W.Q., De Felice F.G., Fernandez S., Chen H., Lambert M.P., Quon M.J., et al. Amyloid beta oligomers induce impairment of neuronal insulin receptors. [Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't]. The FASEB journal: Official Publication of the Federation of American Societies for Experimental Biology 2008, 22(1):246-260.
238. Zhao X., MacBride M.M., Peterson B.R., Pfaff D.W., Vasudevan N. Calcium flux in neuroblastoma cells is a coupling mechanism between non-genomic and genomic modes of estrogens. Neuroendocrinology 2005, 81(3):174-182.
239. Znamensky V., Akama K.T., McEwen B.S., Milner T.A. Estrogen levels regulate the subcellular distribution of phosphorylated Akt in hippocampal CA1 dendrites. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience 2003, 23(6):2340-2347.